Company overview
Cleveland Diagnostics develops novel blood-based diagnostic tests for early cancer detection, focusing on prostate cancer with its IsoPSA test to reduce unnecessary biopsies. The company's IsoClear platform analyzes protein structural differences for higher accuracy and specificity in identifying cancer biomarkers. They offer lab-friendly, affordable tests expanding to additional cancers, supported by partnerships like Quest Diagnostics.
Cleveland Diagnostics is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include isopsa test, prostate cancer diagnostics, isoclear platform, cancer blood tests, sia technology.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Cleveland Diagnostics include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.clevelanddx.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- isopsa test, prostate cancer diagnostics, isoclear platform, cancer blood tests, sia technology
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is IsoPSA and its primary use?
- IsoPSA is a blood test that measures protein structural differences to detect prostate cancer risk and high-grade disease, helping rule out unnecessary biopsies with greater accuracy.
- What technology powers Cleveland Diagnostics' tests?
- The IsoClear platform and Solvent Interaction Analysis (SIA) technology analyze protein structures in blood to determine biomarker origins from cancer cells, improving diagnostic specificity.
- What are the company's partnerships and capabilities?
- Cleveland Diagnostics partners with Quest Diagnostics for expanded IsoPSA access and has collaborations like Genomic Health; they operate a state-of-the-art facility for testing, R&D, and scalability in cancer diagnostics.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
